Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony C Faber

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 12, 2013
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1Hiromichi Ebi, Carlotta Costa, Anthony C Faber, et al.
Elife|February 17, 2015
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathwaysS Michael Rothenberg, Kyle Concannon, Sarah Cullen, et al.
Molecular Oncology|July 12, 2020
Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-X<sub>L</sub> -BAX interactionTareq Saleh, Valerie J Carpenter, Liliya Tyutyunyk-Massey, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2009
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibitionAnthony C Faber, Danan Li, Youngchul Song, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 11, 2014
Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutationsHiromichi Ebi, Isao Oze, Takayuki Nakagawa, et al.
Cancer Research|March 29, 2014
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancersAaron N Hata, Alan Yeo, Anthony C Faber, et al.
Cancer Cell|December 30, 2014
Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancerCarlotta Costa, Hiromichi Ebi, Miriam Martini, et al.
Cancer Research|March 11, 2010
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activationBirgit Schoeberl, Anthony C Faber, Danan Li, et al.
Molecular Cancer Therapeutics|July 28, 2021
Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing SarcomaDaniel A R Heisey, Sheeba Jacob, Timothy L Lochmann, et al.
Cancer Letters|March 1, 2014
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancerJatin Roper, Mark J Sinnamon, Erin M Coffee, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Proceedings of the National Academy of Sciences of the United States of America|December 12, 2013
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1Hiromichi Ebi, Carlotta Costa, Anthony C Faber, et al.
Elife|February 17, 2015
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathwaysS Michael Rothenberg, Kyle Concannon, Sarah Cullen, et al.
Molecular Oncology|July 12, 2020
Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-X<sub>L</sub> -BAX interactionTareq Saleh, Valerie J Carpenter, Liliya Tyutyunyk-Massey, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2009
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibitionAnthony C Faber, Danan Li, Youngchul Song, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 11, 2014
Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutationsHiromichi Ebi, Isao Oze, Takayuki Nakagawa, et al.
Cancer Research|March 29, 2014
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancersAaron N Hata, Alan Yeo, Anthony C Faber, et al.
Cancer Cell|December 30, 2014
Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancerCarlotta Costa, Hiromichi Ebi, Miriam Martini, et al.
Cancer Research|March 11, 2010
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activationBirgit Schoeberl, Anthony C Faber, Danan Li, et al.
Molecular Cancer Therapeutics|July 28, 2021
Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing SarcomaDaniel A R Heisey, Sheeba Jacob, Timothy L Lochmann, et al.
Cancer Letters|March 1, 2014
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancerJatin Roper, Mark J Sinnamon, Erin M Coffee, et al.
Pageof 8